Short- and long-term effects of xuezhikang, an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levels (Q44496513)

3 December 2017

Short- and long-term effects of xuezhikang, an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levels (English)

1 reference

3 December 2017

Yan-jun Jia

1

1 reference

3 December 2017

Yan Zhang

2

1 reference

3 December 2017

Jun Liu

3

1 reference

3 December 2017

Yuan-lin Guo

4

1 reference

3 December 2017

Rui-xia Xu

5

1 reference

3 December 2017

Jian-jun Li

6

1 reference

3 December 2017

4 July 2014

1 reference

Chinese Journal of Integrated Traditional and Western Medicine

3 December 2017

1 reference

3 December 2017

22

1 reference

3 December 2017

96-100

1 reference

3 December 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/s11655-014-1846-y

3 December 2017

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-1846-Y

Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-1846-Y

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-1846-Y

Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-1846-Y

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-1846-Y

Structure and physiologic function of the low-density lipoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-1846-Y

Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-1846-Y

Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-1846-Y

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-1846-Y

Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-1846-Y

Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-1846-Y

Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-1846-Y

Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-1846-Y

Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-1846-Y

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-1846-Y

Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-1846-Y

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-1846-Y

Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-1846-Y

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-1846-Y

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-014-1846-Y

Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24993334

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24993334

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11655-014-1846-Y

1 reference

release_kzaf64xaovd7flz65v2ixsch5a

3 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kzaf64xaovd7flz65v2ixsch5a

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference